The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Infliximab and Biosimilar Market Research Report 2024
Synopsis
Infliximab (trade names Remicade among others) is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-α) and is used to treat autoimmune diseases.
The global Infliximab and Biosimilar market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Infliximab and Biosimilar, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Infliximab and Biosimilar.
Report Scope
The Infliximab and Biosimilar market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Infliximab and Biosimilar market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Infliximab and Biosimilar manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Janssen Biotech
Merck and Co.
Pfizer
Segment by Type
Infliximab
Infliximab-dyyb
Infliximab-abda
Segment by Application
Crohn's Disease
Pediatric Crohn's Disease
Ulcerative Colitis
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic Arthritis
Plaque Psoriasis
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Infliximab and Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Infliximab and Biosimilar in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Infliximab (trade names Remicade among others) is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-α) and is used to treat autoimmune diseases.
The global Infliximab and Biosimilar market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Infliximab and Biosimilar, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Infliximab and Biosimilar.
Report Scope
The Infliximab and Biosimilar market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Infliximab and Biosimilar market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Infliximab and Biosimilar manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Janssen Biotech
Merck and Co.
Pfizer
Segment by Type
Infliximab
Infliximab-dyyb
Infliximab-abda
Segment by Application
Crohn's Disease
Pediatric Crohn's Disease
Ulcerative Colitis
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic Arthritis
Plaque Psoriasis
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Infliximab and Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Infliximab and Biosimilar in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Infliximab and Biosimilar Market Overview
1.1 Product Overview and Scope of Infliximab and Biosimilar
1.2 Infliximab and Biosimilar Segment by Type
1.2.1 Global Infliximab and Biosimilar Market Value Comparison by Type (2024-2030)
1.2.2 Infliximab
1.2.3 Infliximab-dyyb
1.2.4 Infliximab-abda
1.3 Infliximab and Biosimilar Segment by Application
1.3.1 Global Infliximab and Biosimilar Market Value by Application: (2024-2030)
1.3.2 Crohn's Disease
1.3.3 Pediatric Crohn's Disease
1.3.4 Ulcerative Colitis
1.3.5 Rheumatoid Arthritis
1.3.6 Ankylosing Spondylitis
1.3.7 Psoriatic Arthritis
1.3.8 Plaque Psoriasis
1.4 Global Infliximab and Biosimilar Market Size Estimates and Forecasts
1.4.1 Global Infliximab and Biosimilar Revenue 2019-2030
1.4.2 Global Infliximab and Biosimilar Sales 2019-2030
1.4.3 Global Infliximab and Biosimilar Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Infliximab and Biosimilar Market Competition by Manufacturers
2.1 Global Infliximab and Biosimilar Sales Market Share by Manufacturers (2019-2024)
2.2 Global Infliximab and Biosimilar Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Infliximab and Biosimilar Average Price by Manufacturers (2019-2024)
2.4 Global Infliximab and Biosimilar Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Infliximab and Biosimilar, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Infliximab and Biosimilar, Product Type & Application
2.7 Infliximab and Biosimilar Market Competitive Situation and Trends
2.7.1 Infliximab and Biosimilar Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Infliximab and Biosimilar Players Market Share by Revenue
2.7.3 Global Infliximab and Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Infliximab and Biosimilar Retrospective Market Scenario by Region
3.1 Global Infliximab and Biosimilar Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Infliximab and Biosimilar Global Infliximab and Biosimilar Sales by Region: 2019-2030
3.2.1 Global Infliximab and Biosimilar Sales by Region: 2019-2024
3.2.2 Global Infliximab and Biosimilar Sales by Region: 2025-2030
3.3 Global Infliximab and Biosimilar Global Infliximab and Biosimilar Revenue by Region: 2019-2030
3.3.1 Global Infliximab and Biosimilar Revenue by Region: 2019-2024
3.3.2 Global Infliximab and Biosimilar Revenue by Region: 2025-2030
3.4 North America Infliximab and Biosimilar Market Facts & Figures by Country
3.4.1 North America Infliximab and Biosimilar Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Infliximab and Biosimilar Sales by Country (2019-2030)
3.4.3 North America Infliximab and Biosimilar Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Infliximab and Biosimilar Market Facts & Figures by Country
3.5.1 Europe Infliximab and Biosimilar Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Infliximab and Biosimilar Sales by Country (2019-2030)
3.5.3 Europe Infliximab and Biosimilar Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Infliximab and Biosimilar Market Facts & Figures by Country
3.6.1 Asia Pacific Infliximab and Biosimilar Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Infliximab and Biosimilar Sales by Country (2019-2030)
3.6.3 Asia Pacific Infliximab and Biosimilar Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Infliximab and Biosimilar Market Facts & Figures by Country
3.7.1 Latin America Infliximab and Biosimilar Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Infliximab and Biosimilar Sales by Country (2019-2030)
3.7.3 Latin America Infliximab and Biosimilar Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Infliximab and Biosimilar Market Facts & Figures by Country
3.8.1 Middle East and Africa Infliximab and Biosimilar Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Infliximab and Biosimilar Sales by Country (2019-2030)
3.8.3 Middle East and Africa Infliximab and Biosimilar Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Infliximab and Biosimilar Sales by Type (2019-2030)
4.1.1 Global Infliximab and Biosimilar Sales by Type (2019-2024)
4.1.2 Global Infliximab and Biosimilar Sales by Type (2025-2030)
4.1.3 Global Infliximab and Biosimilar Sales Market Share by Type (2019-2030)
4.2 Global Infliximab and Biosimilar Revenue by Type (2019-2030)
4.2.1 Global Infliximab and Biosimilar Revenue by Type (2019-2024)
4.2.2 Global Infliximab and Biosimilar Revenue by Type (2025-2030)
4.2.3 Global Infliximab and Biosimilar Revenue Market Share by Type (2019-2030)
4.3 Global Infliximab and Biosimilar Price by Type (2019-2030)
5 Segment by Application
5.1 Global Infliximab and Biosimilar Sales by Application (2019-2030)
5.1.1 Global Infliximab and Biosimilar Sales by Application (2019-2024)
5.1.2 Global Infliximab and Biosimilar Sales by Application (2025-2030)
5.1.3 Global Infliximab and Biosimilar Sales Market Share by Application (2019-2030)
5.2 Global Infliximab and Biosimilar Revenue by Application (2019-2030)
5.2.1 Global Infliximab and Biosimilar Revenue by Application (2019-2024)
5.2.2 Global Infliximab and Biosimilar Revenue by Application (2025-2030)
5.2.3 Global Infliximab and Biosimilar Revenue Market Share by Application (2019-2030)
5.3 Global Infliximab and Biosimilar Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Janssen Biotech
6.1.1 Janssen Biotech Corporation Information
6.1.2 Janssen Biotech Description and Business Overview
6.1.3 Janssen Biotech Infliximab and Biosimilar Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Janssen Biotech Infliximab and Biosimilar Product Portfolio
6.1.5 Janssen Biotech Recent Developments/Updates
6.2 Merck and Co.
6.2.1 Merck and Co. Corporation Information
6.2.2 Merck and Co. Description and Business Overview
6.2.3 Merck and Co. Infliximab and Biosimilar Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Merck and Co. Infliximab and Biosimilar Product Portfolio
6.2.5 Merck and Co. Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Corporation Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Infliximab and Biosimilar Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Pfizer Infliximab and Biosimilar Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Infliximab and Biosimilar Industry Chain Analysis
7.2 Infliximab and Biosimilar Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Infliximab and Biosimilar Production Mode & Process
7.4 Infliximab and Biosimilar Sales and Marketing
7.4.1 Infliximab and Biosimilar Sales Channels
7.4.2 Infliximab and Biosimilar Distributors
7.5 Infliximab and Biosimilar Customers
8 Infliximab and Biosimilar Market Dynamics
8.1 Infliximab and Biosimilar Industry Trends
8.2 Infliximab and Biosimilar Market Drivers
8.3 Infliximab and Biosimilar Market Challenges
8.4 Infliximab and Biosimilar Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
